We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

An Observational Study on Teriflunomide-exposed Pregnancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03198351
Recruitment Status : Recruiting
First Posted : June 26, 2017
Last Update Posted : January 9, 2023
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

To evaluate any potential increase in the risk of major birth defects, in the first year of life, in teriflunomide-exposed pregnancies.

Secondary Objective:

To evaluate the potential effect of teriflunomide-exposure on other adverse pregnancy outcomes including any potential pattern of minor birth defects, spontaneous abortion, stillbirth, preterm delivery, small for gestational age at birth and at 1 year follow-up.

Condition or disease Intervention/treatment
Multiple Sclerosis Drug: Teriflunomide (HMR1726)

Detailed Description:

The total study duration per participant is approximately up to 2 years.

  • This is a prospective, observational study (no intervention), ie, patient registry.
  • The statistical analysis for the cohort study describe baseline characteristics in all three cohorts, and then will compare pregnancy outcomes in cohort 1 to cohort 2 and secondarily to cohort 3.
  • For the "registry" group, without comparisons, only descriptive statistics of pregnancy outcomes will be summarized.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 325 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: Teriflunomide Pregnancy Outcome Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project
Actual Study Start Date : April 25, 2013
Estimated Primary Completion Date : July 3, 2023
Estimated Study Completion Date : July 3, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pregnancy

Group/Cohort Intervention/treatment
Cohort I
Pregnant women with a confirmed diagnosis of multiple sclerosis (MS) and teriflunomide exposure during the current pregnancy
Drug: Teriflunomide (HMR1726)

Pharmaceutical form: tablet

Route of administration: oral

Other Name: Aubagio

Cohort II
Pregnant women with MS not exposed to teriflunomide during the current pregnancy
Cohort III
Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen
"Registry" group (not eligible for cohorts)
Women who contact the OTIS registry study staff and who do not meet the criteria for the prospective study, for example, at time of contacting the study, having known prenatal diagnosis of congenital defect, or gestation weeks greater than 20 following a first trimester teriflunomide exposure, etc.; these participants will not be included in the primary analysis for the cohort study.

Primary Outcome Measures :
  1. Rate of major structural defects in live born infants [ Time Frame: Up to the infant's first year birthday ]

Secondary Outcome Measures :
  1. Proportion of major structural defects in all pregnancies [ Time Frame: up to 1 year of age in infant ]
  2. Specific pattern of 3 or more minor structural defects in live born infants receiving the exam [ Time Frame: up to one year after birth ]
  3. Rate of spontaneous abortion [ Time Frame: date of conception to 20 weeks gestation ]
  4. Rate of preterm delivery [ Time Frame: live birth prior to 37 weeks gestation ]
  5. Proportion of infants who are small for gestational age (less than or equal to the 10th percentile for gestational age and sex) on weight, length, or head circumference [ Time Frame: at birth ]
  6. Proportion of infants less than or equal to the 10th percentile for sex and age on weight, length, or head circumference at 1 year postnatal evaluation [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
-Pregnant women will be enrolled at various stages of gestation depending when they are included in the registry; then the pregnant outcome will be followed and for live infants, the follow up will be up to the children's 1 year birthday.

Inclusion criteria :

  • Pregnant women who have provided an oral and/or written consent to enroll no later than 20 completed weeks from last menstrual period (LMP).
  • Pregnant women who agree to the conditions and requirements of the study including the interview schedule, release of medical records, and the physical examination of live born infants (up to 1 year post birth).
  • Pregnant women with a diagnosis of MS and teriflunomide exposure during pregnancy (Cohort 1).
  • Pregnant women with MS but not exposed teriflunomide during pregnancy (Cohort 2).
  • Healthy pregnant women who do not have a known diagnosis of MS and have no known exposure to a known human teratogen during pregnancy (Cohort 3).

Exclusion criteria:

  • Pregnant women who come in first contact with the project after prenatal diagnosis of a major structural defect (Cohort 1, 2, 3). This does not apply to the "registry" group.
  • Pregnant women who first come in contact with the project after 20 completed weeks' gestation (Cohort 1, 2, 3). This does not apply to the "registry" group.
  • Pregnant women who had previously enrolled in the study for a previous pregnancy (only 1 pregnancy, per woman, maybe registered) (Cohort 1, 2, 3). This does not apply to the "registry" group.
  • Retrospectively reported cases (Cohort 1, 2, 3). This does not apply to the "registry" group.
  • Pregnant women with exposures to teriflunomide commencing after the 12th week post-LMP (Cohort 1). This does not apply to the "registry" group.
  • Pregnant women who had previously been treated with teriflunomide if they had received any dose of the drug within 2 years prior to the index pregnancy and do not have documented blood levels below 0.02 mcg/mL prior to pregnancy (Cohort 2).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03198351

Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext 1 then # Contact-US@sanofi.com

Layout table for location information
United States, California
University of California at San Diego-Site Number:001 Recruiting
San Diego, California, United States, 92093
Investigational Site Number :002 Recruiting
Canada, Canada
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Additional Information:

Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT03198351    
Other Study ID Numbers: OBS13499
U1111-1183-8711 ( Other Identifier: UTN )
First Posted: June 26, 2017    Key Record Dates
Last Update Posted: January 9, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Immunosuppressive Agents
Immunologic Factors